Document is current
Any future updates will be listed below
-
Authors
de Matos Simoes, Ricardo
Shirasaki, Ryosuke
Downey-Kopyscinski, Sondra L.
Matthews, Geoffrey M.
Barwick, Benjamin G. http://orcid.org/0000-0001-9810-3566
Gupta, Vikas A. http://orcid.org/0000-0002-8980-2338
Dupéré-Richer, Daphné
Yamano, Shizuka
Hu, Yiguo http://orcid.org/0000-0002-3973-2140
Sheffer, Michal
Dhimolea, Eugen
Dashevsky, Olga
Gandolfi, Sara
Ishiguro, Kazuya
Meyers, Robin M.
Bryan, Jordan G. http://orcid.org/0000-0002-4984-0516
Dharia, Neekesh V.
Hengeveld, Paul J.
Brüggenthies, Johanna B.
Tang, Huihui
Aguirre, Andrew J. http://orcid.org/0000-0002-0701-6203
Sievers, Quinlan L.
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Glassner, Brian J.
Ott, Christopher J. http://orcid.org/0000-0001-6142-7241
Bradner, James E. http://orcid.org/0000-0002-2718-4415
Kwiatkowski, Nicholas P.
Auclair, Daniel
Levy, Joan
Keats, Jonathan J. http://orcid.org/0000-0003-4375-7399
Groen, Richard W. J.
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Culhane, Aedin C. http://orcid.org/0000-0002-1395-9734
McFarland, James M. http://orcid.org/0000-0001-9978-480X
Dempster, Joshua M. http://orcid.org/0000-0002-3634-9576
Licht, Jonathan D. http://orcid.org/0000-0002-3942-1369
Boise, Lawrence H. http://orcid.org/0000-0001-9436-8815
Hahn, William C. http://orcid.org/0000-0003-2840-9791
Vazquez, Francisca http://orcid.org/0000-0002-2857-4685
Tsherniak, Aviad http://orcid.org/0000-0002-3797-1877
Mitsiades, Constantine S. http://orcid.org/0000-0003-2321-8005
- License Information
-
More Information
Article History
Received: 16 October 2021
Accepted: 29 March 2023
First Online: 26 May 2023
Competing interests
: R.S. serves research funding from FIMECS and honoraria from Janssen Pharma. G.M.M. is an employee of Aculeus Therapeutics. N.V.D. is an employee of Genentech, a member of the Roche Group. A.J.A. has consulted for Anji Pharmaceuticals, Arrakis Therapeutics, AstraZeneca, Boehringer Ingelheim, Oncorus, Inc., Merck & Co., Inc., Mirati Therapeutics, Nimbus Therapeutics, Plexium, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals and T-knife Therapeutics. A.J.A. holds equity in Riva Therapeutics. A.J.A. has research funding from Bristol Myers Squibb, Deerfield, Inc., Eli Lilly, Mirati Therapeutics, Novartis, Novo Ventures, Revolution Medicines and Syros Pharmaceuticals. C.J.O. has received research support from Gilead, Scorpion Therapeutics and eFFECTOR Therapeutics. J.M.D. is a consultant and holds equity in Jumble Therapeutics. B.L.E. has received research funding from Celgene, Deerfield, Novartis and Calico and consulting fees from GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Inc., TenSixteen Bio, Skyhawk Therapeutics and Exo Therapeutics. J.E.B. is a Scientific Founder of Syros Pharmaceuticals, SHAPE Pharmaceuticals, Acetylon Pharmaceuticals, Tensha Therapeutics (now Roche) and C4 Therapeutics and is the inventor on intellectual property licensed to these entities. J.E.B. has recently served as an executive and shareholder in Novartis AG. N.K. is currently an employee of Kymera Therapeutics, Inc. N.S.G. is a founder, science advisory board member (SAB) and equity holder in Syros, C4, Allorion, Lighthorse, Voronoi, Inception, Matchpoint, CobroVentures, GSK, Shenandoah (board member), Larkspur (board member) and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. J.J.K. has received research funding from Amgen, Genentech and Janssen. J.M.M. has received research funding from the Dependency Map Consortium. W.C.H. is a consultant for Thermo Fisher, Solasta Ventures, MPM Capital, KSQ Therapeutics, Frontier Medicines, Tyra Biosciences, Function Oncology, Jubilant Therapeutics, Riva Therapeutics, RAPPTA Therapeutics, Calyx and Serinus Biosciences. L.H.B. is a consultant for and receives honoraria and research funding from AstraZeneca, and is a consultant for Genentech and Abbvie. J.D.L. receives research funding from Ipsen/Epizyme and is consultant for AstraZeneca. A.T. is a consultant for Cedilla Therapeutics, Foghorn Therapeutics and The Center for Protein Degradation (Deerfield), and is a SAB member and holds equity in Turbine Simulated Cell Technologies. F.V. receives research support from the Dependency Map Consortium, Bristol Myers Squibb, Novo Ventures and Riva Therapeutics, and has shares and is a consultant for Riva Therapeutics. C.S.M. serves on the Scientific Advisory Board of Adicet Bio and discloses consultant/honoraria from Genentech, Fate Therapeutics, Ionis Pharmaceuticals, FIMECS, Secura Bio and Oncopeptides, and research funding from Janssen/Johnson & Johnson, EMD Serono, Arch Oncology, Karyopharm, Sanofi, Nurix, BMS, H3 Biomedicine/Eisai, Springworks, Abcuro and Novartis. The remaining authors declare no competing interests.
